Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01434173 · ClinicalTrials.gov registry record

Risk of Acute Liver Injury in Users of Antimicrobials

A clinical trial, sponsored by Bayer.

Completed
Registry status
1,299,056
Enrollment target

NCT01434173: Completed study, sponsored by Bayer.

NCT01434173 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 1,299,056 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01434173 has completed, sponsored by Bayer.

COMPLETED
Registry status
1,299,056 participants
Enrollment target

Study Summary

Moxifloxacin is a broad-spectrum antibacterial agent used to treat common community-acquired respiratory tract infections, complicated intra-abdominal infections, and pelvic inflammatory disease. In the clinical development program, moxifloxacin was associated with some hepatic adverse drug reactions. To evaluate further the hepatic safety profile of moxifloxacin, a retrospective cohort study with nested case-control analysis will be conducted to assess the rate of noninfectious acute liver injury among new users of moxifloxacin and of other antimicrobials prescribed for similar indications, including amoxicillin, amoxicillin plus clavulanic acid, cefuroxime, clarithromycin, doxycycline, levofloxacin, and telithromycin. The study will be implemented in the population included in the HealthCore Integrated Research Database (HIRD). Eligible patients are adults aged 18 years and older with continuous enrollment in the HIRD for at least 6 months before their first claim for a prescription for a study antimicrobial. Follow-up will start at the date of the first prescription until the date of the earliest of the following events: noninfectious acute liver injury, occurrence of an exclusion criterion, end of study period, disenrollment from database, or death. Patients with chronic alcoholism or cirrhosis, infectious hepatitis, HIV/AIDS, or pregnant women will not be included.

Interventions

  • DRUG Moxifloxacin (Avelox, BAY12-8039)
  • DRUG Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin

Trial Details

FieldValue
Enrollment Target 1,299,056 participants
Start Date 2001-07
Est. Completion 2009-03
Bayer

591 total trials

What the finished NCT01434173 record still lists

NCT01434173 is an observational study that tracks outcomes without assigning an intervention. Its 1,299,056 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 2 interventions - of which Moxifloxacin (Avelox, BAY12-8039) is the first listed.

NCT01434173 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01434173 about?

NCT01434173 is a clinical study titled "Risk of Acute Liver Injury in Users of Antimicrobials". Moxifloxacin is a broad-spectrum antibacterial agent used to treat common community-acquired respiratory tract infections, complicated intra-abdominal infections, and pelvic inflammatory disease. In the clinical development program, moxifloxacin was associated with some hepatic adverse drug reaction...

What is the current status of trial NCT01434173?

This trial is currently completed. The enrollment target is 1,299,056 participants. The study started on 2001-07. Estimated completion is 2009-03.

What interventions are being tested in trial NCT01434173?

The interventions under investigation include: Moxifloxacin (Avelox, BAY12-8039) (DRUG), Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin (DRUG).

Who is sponsoring clinical trial NCT01434173?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07022951 · 1,200,000 participants

    The Million Anesthesia Cases Study (MACS) - a Cohort Study of Preoperative Fasting and Perioperative Outcomes

  • NCT05066763 · 1,000,000 participants

    Parkinson's Foundation Surveys

  • NCT07075341 · 1,000,000 participants

    Healthy Living BEYOND Weight Study

  • NCT07224685 · 1,000,000 participants

    A Study of Mayo Clinic CV Research Heart & Voice Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01434173, the US trial registry maintained by the National Library of Medicine. NCT01434173 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.